NCT03769129View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

NARecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2029

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab

PROCEDURE

microwave ablation

microwave ablation

Trial Locations (1)

Unknown

RECRUITING

zhang Zhenfeng, Guangzhou

All Listed Sponsors

lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER